96 related articles for article (PubMed ID: 10560341)
1. A preliminary study for clinical pharmacokinetics of oral fluorine anticancer medicines using the commercial MRI system 19F-MRS.
Ikehira H; Girard F; Obata T; Ito H; Yoshitomi H; Miyazaki M; Nakajima N; Kamei H; Kanazawa Y; Takano H; Ito H; Tanada S; Sasaki Y
Br J Radiol; 1999 Jun; 72(858):584-9. PubMed ID: 10560341
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment energy status of primary rat tumours as the best predictor of response to 5-fluorouracil chemotherapy: a magnetic resonance spectroscopy study in vivo.
Lemaire LP; McSheehy PM; Griffiths JR
Cancer Chemother Pharmacol; 1998; 42(3):201-9. PubMed ID: 9685055
[TBL] [Abstract][Full Text] [Related]
3. Simultaneous 3D NMR spectroscopy of proton-decoupled fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy.
Gonen O; Murphy-Boesch J; Li CW; Padavic-Shaller K; Negendank WG; Brown TR
Magn Reson Med; 1997 Feb; 37(2):164-9. PubMed ID: 9001138
[TBL] [Abstract][Full Text] [Related]
4. Alterations of intratumoral pharmacokinetics of 5-fluorouracil in head and neck carcinoma during simultaneous radiochemotherapy.
Schlemmer HP; Becker M; Bachert P; Dietz A; Rudat V; Vanselow B; Wollensack P; Zuna I; Knopp MV; Weidauer H; Wannenmacher M; van Kaick G
Cancer Res; 1999 May; 59(10):2363-9. PubMed ID: 10344745
[TBL] [Abstract][Full Text] [Related]
5. Human hepatic carbohydrate metabolism. Dynamic observation using 13C MRS without proton decoupling.
Ikehira H; Obata T; Koga M; Yoshida K
Acta Radiol; 1997 Nov; 38(6):998-1002. PubMed ID: 9394656
[TBL] [Abstract][Full Text] [Related]
6. Quantitative 19F MR spectroscopy at 3 T to detect heterogeneous capecitabine metabolism in human liver.
Klomp D; van Laarhoven H; Scheenen T; Kamm Y; Heerschap A
NMR Biomed; 2007 Aug; 20(5):485-92. PubMed ID: 17131325
[TBL] [Abstract][Full Text] [Related]
7. [In-vivo 19F-MRS study of 5-fluorouracil (5-FU) metabolism on tumors].
Harada M; Nishitani H; Shirahama T; Koga K; Miura I
Gan To Kagaku Ryoho; 1991 Jan; 18(1):75-80. PubMed ID: 1899014
[TBL] [Abstract][Full Text] [Related]
8. Optimization of localized 19F magnetic resonance spectroscopy for the detection of fluorinated drugs in the human liver.
Klomp DW; Van Laarhoven HW; Kentgens AP; Heerschap A
Magn Reson Med; 2003 Aug; 50(2):303-8. PubMed ID: 12876706
[TBL] [Abstract][Full Text] [Related]
9. Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil.
van Laarhoven HW; Klomp DW; Rijpkema M; Kamm YL; Wagener DJ; Barentsz JO; Punt CJ; Heerschap A
NMR Biomed; 2007 Apr; 20(2):128-40. PubMed ID: 17006886
[TBL] [Abstract][Full Text] [Related]
10. Effects of hepatic impairment on the metabolism of fructose and 5-fluorouracil, as studied in fatty liver models using in vivo 31P-MRS and 19F-MRS.
Otsuka H; Harada M; Koga K; Nishitani H
Magn Reson Imaging; 1999 Feb; 17(2):283-90. PubMed ID: 10215484
[TBL] [Abstract][Full Text] [Related]
11. Fluorine nuclear magnetic resonance spectroscopy of human biofluids in the field of metabolic studies of anticancer and antifungal fluoropyrimidine drugs.
Malet-Martino M; Gilard V; Desmoulin F; Martino R
Clin Chim Acta; 2006 Apr; 366(1-2):61-73. PubMed ID: 16337167
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous 3D NMR spectroscopy of fluorine and phosphorus in human liver during 5-fluorouracil chemotherapy.
Li CW; Gonen O
Magn Reson Med; 1996 Jun; 35(6):841-7. PubMed ID: 8744011
[TBL] [Abstract][Full Text] [Related]
13. In vivo monitoring of capecitabine metabolism in human liver by 19fluorine magnetic resonance spectroscopy at 1.5 and 3 Tesla field strength.
van Laarhoven HW; Klomp DW; Kamm YJ; Punt CJ; Heerschap A
Cancer Res; 2003 Nov; 63(22):7609-12. PubMed ID: 14633676
[TBL] [Abstract][Full Text] [Related]
14. 19F-MRS studies of fluorinated drugs in humans.
Wolf W; Presant CA; Waluch V
Adv Drug Deliv Rev; 2000 Mar; 41(1):55-74. PubMed ID: 10699305
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of tegafur in rat liver observed by in vivo 19F magnetic resonance spectroscopy and chromatography.
Harada M; Nishitani H; Koga K; Miura I; Umeno Y
Jpn J Cancer Res; 1992 Apr; 83(4):387-91. PubMed ID: 1506273
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy.
Glaholm J; Leach MO; Collins D; al Jehazi B; Sharp JC; Smith TA; Adach J; Hind A; McCready VR; White H
Br J Radiol; 1990 Jul; 63(751):547-53. PubMed ID: 2390689
[TBL] [Abstract][Full Text] [Related]
17. Novel non-invasive probes for measuring tumor-hypoxia by 19F-magnetic resonance spectroscopy (19F-MRS). Studies in the SCCVII/C3H murine model.
Papadopoulou MV; Pouremad R; Bloomer WD; Wyrwicz A
Anticancer Res; 2006; 26(5A):3259-63. PubMed ID: 17094438
[TBL] [Abstract][Full Text] [Related]
18. Local disposition kinetics of floxuridine after intratumoral and subcutaneous injection as monitored by [19F]-nuclear magnetic resonance spectroscopy in vivo.
Port R; Hanisch F; Becker M; Bachert P; Zeller J
Cancer Chemother Pharmacol; 1999; 44(1):65-73. PubMed ID: 10367751
[TBL] [Abstract][Full Text] [Related]
19. Proton-decoupled 19F spectroscopy of 5-FU catabolites in human liver.
Murphy-Boesch J; Li CW; He L; Padavic-Shaller KA; Negendank W; Brown TR
Magn Reson Med; 1997 Mar; 37(3):321-6. PubMed ID: 9055218
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance spectroscopy for measuring the biodistribution and in situ in vivo pharmacokinetics of fluorinated compounds: validation using an investigation of liver and heart disposition of tecastemizole.
Schneider E; Bolo NR; Frederick B; Wilkinson S; Hirashima F; Nassar L; Lyoo IK; Koch P; Jones S; Hwang J; Sung Y; Villafuerte RA; Maier G; Hsu R; Hashoian R; Renshaw PF
J Clin Pharm Ther; 2006 Jun; 31(3):261-73. PubMed ID: 16789992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
